Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience.
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
/ genetics
Child
Child, Preschool
Chromosome Inversion
Chromosomes, Human, Pair 21
/ genetics
Chromosomes, Human, Pair 8
/ genetics
Core Binding Factors
/ genetics
Female
Follow-Up Studies
Humans
Infant
Leukemia, Myeloid, Acute
/ drug therapy
Male
Prognosis
Retrospective Studies
Survival Rate
Translocation, Genetic
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
5
6
2020
medline:
1
1
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Childhood acute myeloid leukemia (AML) harboring core binding factor (CBF)-associated translocations are considered as a favorable cytogenetic subgroup. The 2 major subtypes of CBF-AML include t(8;21) and inversion of chromosome 16, accounting for ∼25% of patients. Because of expensive and toxic treatment, which may require hospitalization during the entire course of induction chemotherapy, most of the centers in Pakistan neither workup for this low-risk entity nor offer curative treatment. Therefore, we adopted an approach of screening AML cases for the presence of CBF with the rationale of offering curative treatment to this subgroup. Data of 244 cases were reviewed, and translocations were found in 72 (34%) patients among them, 59 (82%) had t(8;21) and 13 (18%) showed inversion of chromosome 16. The event-free survival with and without abandonment was 36% and 40%, respectively. Among 44 patients who completed treatment, 26 (59%) are leukemia-free, while 18 (41%) relapsed. None of the relapsed patients received salvage chemotherapy or hematopoietic stem cell transplant. Treatment-related mortality and abandonment was found in 24% and 10% of patients, respectively. The frequency of CBF-AML is higher in our study; however, poor outcome demands holistic measures in supportive care to improve the survival.
Identifiants
pubmed: 32496446
doi: 10.1097/MPH.0000000000001853
pii: 00043426-202008000-00015
doi:
Substances chimiques
Biomarkers, Tumor
0
Core Binding Factors
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e423-e427Références
Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187–3205.
Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005a;19:2030–2042.
Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543–552.
Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML cooperative group. J Clin Oncol. 2009;27:4007–4013.
Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96:1478–1487.
Rubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia. 2002;16:2072–2077.
Pession A, Rondelli R, Basso G, et al. AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19:2043–2053.
Entz-Werle N, Suciu S, van der Werff ten Bosch J, et al. Results of 58,872 and 58,921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs. allogeneic bone marrow transplantation in first complete remission: The EORTC Children Leukemia Group report. Leukemia. 2005;19:2072–2081.
Betts DR, Ammann RA, Hirt A, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007;78:468–476.
Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28:2674–2681.
Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol. 2008;35:410–417.
Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155:366–376.
Jastaniah W, Alsultan A, Al Daama S, et al. Is the outcome of childhood acute myeloid leukemia with t(8;21) inferior in Saudi Arabia? A multicenter SAPHOS leukemia group study. J App Hematol. 2017;8:41.
Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: Results from an international retrospective study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2015;33:4247–4258.
Ghafoor T, Sharif I, Ashraf T, et al. Paediatric acute myeloid leukaemia; clinical characteristics and treatment outcome; experience from a developing country. Int J Adv Res. 2018;6:113–122.
Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19:2130–2138.
Nucifora G, Dickstein JI, Torbenson V, et al. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia. 1994;8:1533–1538.
Ferrara F, Del Vecchio L. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity. Haematologica. 2002;87:306–319.
Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462–469.
Von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AMLBFM 98. J Clin Oncol. 2010;28:2682–2689.
Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115:2372–2379.
Khan Y, Bhutta ZA. Nutritional deficiencies in the developing world: current status and opportunities for intervention. Pediatr Clin. 2010;57:1409–1441.
Linga VG, Shreedhara AK, Rau AT, et al. Nutritional assessment of children with hematological malignancies and their subsequent tolerance to chemotherapy. Ochsner J. 2012;12:197–201.
Tandon S, Moulik NR, Kumar A, et al. Effect of pre-treatment nutritional status, folate and vitamin B12 levels on induction chemotherapy in children with acute lymphoblastic leukemia. Indian Pediatr. 2015;52:385–389.
Bansal D, Davidson A, Supriyadi E, et al. SIOP PODC adapted risk stratification and treatment guidelines: recommendations for acute myeloid leukemia in resource-limited settings. Pediatr Blood Cancer. 2019:e28087.
Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–5717.
Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22; q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77.